Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
In recent years the medication options for the treatment of ADHD in children and young people have increased. The National Institute for Health and Clinical Excellence (NICE) produced updated guidelines in 2006. This paper aims to interpret these guidelines by reviewing the medication options in light of relevant research and clinical practice. The properties of methylphenidate, dexamfetamine and atomoxetine are discussed.
Harpin
V A
VA
Ryegate Childrens Centre, Sheffield Children's NHS Foundation Trust, Tapton Crescent Road, Sheffield S10 5DD, UK. val.harpin@sch.nhs.uk
D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003913:Dextroamphetamine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008774:Methylphenidate / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride; D003913:Dextroamphetamine